PRODUCTS

BioSentinel offers an extensive line of products for your botulinum neurotoxin (BoNT) detection needs. Whether determining the potency of BoNT pharmaceuticals, screening and characterizing BoNT inhibitors, or detecting and/or quantifying BoNT concentrations in food and environmental samples, BioSentinel’s assays have sensitivity levels equivalent or better than the mouse LD50 assay. Our fluorescent mix and read assays can be used in high-throughput formats and are able to detect multiple BoNT serotypes in a wide range of complex matrices with minimal equipment needs. BioSentinel’s BoNT detection assays are the new standard for quantifying pharmaceutical BoNT preparations.

BoTest® Botulinum Neurotoxin Detection Kits

These flexible assays provide real-time detection of BoNT proteolytic activity in an optimized reaction buffer. Intended uses include quantification and characterization of BoNT pharmaceutical preparations, drug discovery, high throughput screening applications, and real-time detection applications. Read more

BoTest® Matrix Botulinum Neurotoxin Detection Kits

These serotype-specific assays are robust and sensitive tools for the detection and quantification of BoNT proteolytic activity contained in complex matrices such as pharmaceutical preparations, food samples, blood, and serum. These magnetic bead-based kits are sold as a combination of a serotype-specific Matrix BoNT Immunoprecipitation Kit and the appropriate BoTest® BoNT Detection Kit. Read more

Matrix Botulinum Neurotoxin Immunoprecipitation (IP) Kits

The BoNT Immunoprecipitation Kits can be purchased separately to immunoprecipitate, concentrate, and purify BoNT out of a variety of solutions including foods, culture supernatants, serum, and drug substances for user-defined analysis. For quantification of bound BoNT, we recommend the BoTest® Botulinum Neurotoxin Detection Kits described above. Read more

BoLISA® Botulinum Neurotoxin Sandwich ELISAs

The BoLISA kits are serotype-specific and detect and quantify total BoNT mass from liquid matrices using a traditional sandwich ELISA approach. Read more

BoTest® Drug Screening Services for discovery of BoNT antagonists

BioSentinel can screen drug libraries of nearly any size using our BoTest reagents. Please inquire for more information.

ABOUT BIOSENTINEL

MISSION

BioSentinel develops innovative tools and reagents for the study of botulinum neurotoxin (BoNT). Our tests and assays set new standards for speed, sensitivity, and accuracy while at the same time lowering testing costs and removing animal usage.

Our assays detect BoNT in hours with sensitivities that rival that of the mouse bioassay, the “gold standard” for BoNT detection. The assays are easy to use, readily adaptable to various applications, and in the case of the cell-based assay, can directly replace the laborious mouse bioassay.

Our laboratory has been creating technology advancements for improved BoNT research and detection since 2007. We offer a suite of assays for detection and quantification of BoNT in diverse samples such as food, serum, purified toxin, and drug product samples, and the expertise to match you with the right product to further your research.

THE COMPANY

BioSentinel, Inc. (BioSentinel) designs rapid, sensitive tests for the detection of botulinum neurotoxins (BoNTs) as required by the US Department of Defense and the Department of Homeland Security to protect the nation from intentional misuse of these Class A bioterrorism agents. BioSentinel's proprietary rapid detection technology also addresses the needs of pharmaceutical companies who sell botulinum neurotoxin for FDA-approved cosmetic and therapeutic applications.

BioSentinel has a vigorous research and development program that includes a state-of-the-art laboratory in Madison, WI, and partners throughout the US and worldwide. BioSentinel maintains active collaborations with the National Wildlife Health Center, the US Army Medical Research Institute of Chemical Defense (Aberdeen Proving Grounds, MD), and the University of Wisconsin-Madison. BioSentinel is also partnered with private companies who share BioSentinel's goals of developing innovative technologies/platforms for the detection, characterization, and quantification of BoNTs.

The BioSentinel team is uniquely qualified to design BoNT detection technologies for both biodefense programs and pharmaceutical uses and applications. Read more about Our Team.